Analysis of SARS-CoV-2 seroprevalence among the population of the Vladimir Region during the COVID-19 epidemic


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To estimate the level of seroprevalence in the population of the Vladimir Region during the COVID-19 epidemic. Materials and methods. Work was done as part of the first stage of the program to assess herd immunity to SARS-CoV-2 among the population of the Russian Federation according to the common methodology developed by the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being with the participation of the Pasteur Research Institute of Epidemiology and Microbiology. Volunteers were selected using questionnaires and randomization. The analysis included the results of a survey of2,798 volunteers distributed in 7 age groups. The level of IgG specific to SARS- CoV-2 nucleocapsid was determined by enzyme immunoassay. Results. The level of seroprevalence in the population was 10.7%, with a maximum of 25.1% in children aged 1-6 years and a minimum of 7.6% in people aged 18-29 years. No statistically significant differences were found between men and women in indicators. Specific antibodies were detected in 57.1% of the patients who had experienced COVID-19. Contact with a COVID-19 patient was accompanied by seroconversion 1.5 times more often than the population average. Seroconversion was 42.3% in asymptomatic individuals with positive PCR. Among the seropositive volunteers, the proportion of asymptomatic infection amounted to as much as 87.6%. Conclusion. Low seroprevalence in the population contributed to the emergence of the second wave of COVID-19.

全文:

受限制的访问

作者简介

Anna Popova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: depart@gsen.ru
МБ, Head

Elena Ezhlova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: ezhlova_eb@gsen.ru
Cand. Med. Sci., Deputy Head

Albina Melnikova

Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: melnikova_aa@gsen.ru
Deputy Head

Tatiana Danilova

Directorate for the Vladimir Region, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: postmaster@33.rospotrebyfdzor.ru
Head, Directorate for the Vladimir Region

Maksim Bulanov

Center for Hygiene and Epidemiology in the Vladimir Region

Email: sgm@vlades.vladinfo.ru
Chief Physician

Lyudmila Lyalina

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: lyalina@pasteurorg.ru
МБ, Head, Laboratory of Epidemiology of Communicable and Non-Communicable Diseases

Vyacheslav Smirnov

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: vssmi@mail.ru
МБ, Leading Researcher, Laboratory of Molecular Immunology

Areg Totolyan

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: pasteur@pasteurorg.ru
MD, Academician of the Russian Academy of Sciences, Director

参考

  1. Kapikian A.Z. The coronaviruses. Dev. Biol. Stand. 1975; 28: 42-64. PMID: 1092577
  2. Kristoffersen A.W., Nordb0 S.A., Rognlien A.-G.W., Christensen A., D0llner H. Coronavirus causes lower respiratory tract infections less frequently than RSV in hospitalized Norwegian children Pediatr. Infect. Dis. J. 2011; 30(4): 279-83. doi: 10.1097/INF.0b013e3181fcb159
  3. Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W. Et al. Coronavirus as a possible cause of severe acute respiratory syndrome Lancet 2003; 361(9366): 1319-25. doi: 10.1016/S0140-6736(03)13077-2
  4. Hui D.S.C., Zumla A. Severe Acute Respiratory Syndrome Historical, Epidemiologic, and Clinical Features. Infect. Dis. Clin. North Am. 2019; 33(4): 869-89.
  5. Weekly epidemiological record. Relev6 6pid6miologique hebdomadaire 2003; 78(12): 81-8. https://www.who.int/ docstore/wer/pdf/2003/wer7812.pdf
  6. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D.M.E., Fouchier R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012; 367(19): 1814-20. doi: 10.1056/NEJMoa1211721
  7. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/news-room/fact-she-ets/detail/middle -east-re spiratory- syndrome - coronavirus-(mers-cov)
  8. Chan J.F.W., Lau S.K.P., To K.K.W., Cheng V.C.C., Woo P.C.Y., Yuen K.-Y. Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease. Clin. Microbiol. Rev. 2015; 28(2): 465522. doi: 10.1128/CMR.00102-14
  9. Ramshaw R.E., Letourneau I.D., Hong A.Y., Hon J., Morgan J.D., Osborne J.C.P. et al. A database of geopositioned Middle East Respiratory Syndrome Coronavirus occurrences. Sci Data 2019; (6): 318. doi: 10.1038/s41597-019-0330-0
  10. Fagbule O.F., 2019 NOVEL CORONAVIRUS. Ann. Ib. Postgrad. Med. 2019; 17(2): 108-10. PMID: 32669985
  11. WHO. Coronavirus disease 2019 [Internet]. World Health Organization. https://www.who.int/emergencies/diseases/ novel- coronavirus-2019
  12. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Center for Disease Control and Prevention. https://www. cdc.gov/coronavirus/2019-ncov/index.html.2020. [Qted 2020 Feb 14].
  13. Смирнов В.С., Зарубаев В.В. Петленко С.В. Биология возбудителей и контроль гриппа и ОРВИ. СПб: Гиппократ, 2020. 334 c.
  14. Yang D., Han Z., Oppenheim J.J. Alarmins and immunity. Immunol. Rev. 2017; 280(1): 41-56. doi: 10.1111/imr.12577
  15. Смирнов В.С., Тотолян А.А. Врожденный иммунитет при коронавирусной инфекции. Инфекция и иммунитет 2020; 10(2): 259-68. doi: 10.15789/2220-7619-III-1440
  16. Csepregi L., Ehling R.A., Wagner B., Reddy S.T. Immune literacy: reading, writing, and editing adaptive immunity. Science 2020; 23(9): 101519. doi: 10.1016/j.isci.2020.101519
  17. Gavor E., Choong Y.K., Er S.Y., Sivaraman H., Sivaraman J. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Trends in Immunol. 2020. doi: 10.1016/j.it.2020.09.004
  18. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Башкетова Н.С., Фридман Р.К., Лялина Л.В. и др. Популяционный иммунитет к SARS-CoV-2 среди населения Санкт-Петербурга в период эпидемии COVID-19. Проблемы особо опасных инфекций 2020; (3): 124-30. doi: 10.21055/0370-1069-2020-3-124-130
  19. Newcombe R.G. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statist. Med. 1998; 17: 857-87. doi: 10.1002/(sici)1097-0258(19980430)17: 857-887
  20. Herroelen P.H., Martens G.A., De Smet D., Swaerts K., Decavele A.-S. Humoral Immune Response to SARS-CoV-2. Am. J. Clin. Pathol. 2020; 154(5): 610-9. doi: 10.1093/ajcp/ aqaa140
  21. Randolph H.E., Barreiro L. B Herd Immunity: Understanding COVID-19. Immunity 2020; 52(5): 737-41. doi: 10.1016/j. immuni.2020.04.012
  22. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Оглезнева Е.Е., Красноперов А.С., Лялина Л.В. и др. Серопревалентность к SARS-CoV-2 среди населения Белгородской области на фоне эпидемии COVID-19. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(1): 18-24. doi: 10.18565/epidem.2021.11.1.18-24
  23. Snape M.D., Viner R.M. COVID-19 in children and young people. Science 2020; 370(6514): 286-88. DOI: 10.1126/ science.abd6165
  24. Fialkowski A., Gernez Y., Arya P. Weinacht K.G., Kinane T.B., Yonker L.M. Insight into the pediatric and adult dichotomy of COVID-19: Age related differences in the immune response to SARS-CoV-2 infection. Pediatric Pulmonology 2020; 55: 2556-64. doi: 10.1002/ppul.24981

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##